Angiotech Pharma Acquires Product Candidates and Technology Assets from Haemacure CorporationSummaryAngiotech Pharmaceuticals, Inc. a specialty pharmaceutical and medical device company, announced the closing of its acquisition of certain product candidates and technology assets of Haemacure Corporation. Haemacure has been involved in proceedings under Canada's Bankruptcy and Insolvency Act and Chapter 11 of the US Bankruptcy Code. Through an asset sale transaction, Angiotech has acquired all of the relevant research and development activities, manufacturing operations, key personnel, and intellectual property rights necessary to pursue the commercialization of Haemacure's human biomaterial product candidates, namely, fibrin sealant and thrombin hemostat. According to GlobalData the rationale behind this transaction stems from the high opportunity and value that Angiotech could gain from entering the wound care market and the complementing product portfolios the transaction would bring along.ScopeDetails of the deal included- History of previous deals or agreements between the two companies- Rationale behind the deal- Forecast market revenue for the global wound closure devices market- Details of the acquired products in questionReasons to buy- Identify key M&A trends in the medical equipment market- Track competitor product portfolios and acquisition history- Assess future outlook of the company

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Angiotech Pharma Acquires Product Candidates and Technology
Assets from Haemacure Corporation
Published on April 2010
Report Summary
Angiotech Pharma Acquires Product Candidates and Technology Assets from Haemacure Corporation
Summary
Angiotech Pharmaceuticals, Inc. a specialty pharmaceutical and medical device company, announced the closing of its acquisition of
certain product candidates and technology assets of Haemacure Corporation. Haemacure has been involved in proceedings under
Canada's Bankruptcy and Insolvency Act and Chapter 11 of the US Bankruptcy Code. Through an asset sale transaction, Angiotech
has acquired all of the relevant research and development activities, manufacturing operations, key personnel, and intellectual
property rights necessary to pursue the commercialization of Haemacure's human biomaterial product candidates, namely, fibrin
sealant and thrombin hemostat. According to GlobalData the rationale behind this transaction stems from the high opportunity and
value that Angiotech could gain from entering the wound care market and the complementing product portfolios the transaction would
bring along.
Scope
Details of the deal included
- History of previous deals or agreements between the two companies
- Rationale behind the deal
- Forecast market revenue for the global wound closure devices market
- Details of the acquired products in question
Reasons to buy
- Identify key M&A trends in the medical equipment market
- Track competitor product portfolios and acquisition history
- Assess future outlook of the company
Table of Content
1 Table of Contents 1
1.1 List of Tables 1
1.2 List of Figures 1
2 Angiotech Pharma Acquires Product Candidates and Technology Assets from Haemacure Corporation 1
2.1 What is this Report About' 1
2.2 Deal Background 1
2.3 Deal Rationale 2
2.4 The Acquired Products 3
Angiotech Pharma Acquires Product Candidates and Technology Assets from Haemacure Corporation Page 1/4

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
3 Appendix 4
3.1 Research Methodology 4
3.2 Coverage 5
3.3 Secondary Research 5
3.4 Primary Research 5
3.5 Models 5
3.6 Forecasts 5
3.7 Expert Panels 6
3.8 GlobalData Consulting 6
3.9 Contact Us 6
3.10 Disclaimer 6
1.1 List of Tables
Table 1: Wound Closure Devices Market, Global, Revenue ($m), 2009 ' 2016 3
Table 2: Hemaseel Thrombin Haemostatic Agent Product Details 4
Table 3: Hemaseel HMN fibrin sealant-Adhesion Prevention, Product Details 4
Table 4: Hemaseel HMN fibrin sealant-Hemostatis, Product Details 4
1.2 List of Figures
Figure 1: Wound Closure Market, Global, Revenue ($m), 2009 ' 2016 2
Figure 2: GlobalData Methodology 4
Companies mentioned
Angiotech Pharma Acquires Product Candidates and Technology Assets from Haemacure Corporation Page 2/4

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Angiotech Pharma Acquires Product Candidates and Technology Assets from Haemacure Corporation
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 500.00 Quantity: _____
Site License--USD 1 000.00 Quantity: _____
Corporate License--USD 1 500.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Angiotech Pharma Acquires Product Candidates and Technology Assets from Haemacure Corporation Page 3/4

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Angiotech Pharma Acquires Product Candidates and Technology Assets from Haemacure Corporation Page 4/4